Table 1. Clinical and serologic... | American Society of Hematology

Table 1.

Clinical and serologic characteristics of the APS patients

Patient	Clinical manifestations	aCL		LA	Anti-β₂-GPI		ANA^‡	Anti-ENA^‡	Anti-dsDNA^‡
Patient	Clinical manifestations	IgG	IgM^*	LA	IgG	IgM^†	ANA^‡	Anti-ENA^‡	Anti-dsDNA^‡
1	Stroke, recurrent fetal loss	111	5	Pos	2.216	0.118	Neg	Neg	Neg
2	Stroke	87	1	Neg	2.145	0.017	Neg	Neg	Neg
3	Fetal death	98	31	Pos	2.119	1.666	Neg	Neg	Neg

Patient	Clinical manifestations	aCL		LA	Anti-β₂-GPI		ANA^‡	Anti-ENA^‡	Anti-dsDNA^‡
Patient	Clinical manifestations	IgG	IgM^*	LA	IgG	IgM^†	ANA^‡	Anti-ENA^‡	Anti-dsDNA^‡
1	Stroke, recurrent fetal loss	111	5	Pos	2.216	0.118	Neg	Neg	Neg
2	Stroke	87	1	Neg	2.145	0.017	Neg	Neg	Neg
3	Fetal death	98	31	Pos	2.119	1.666	Neg	Neg	Neg

aCL indicates anticardiolipin antibodies; LA, lupus anticoagulant; ANA, antinuclear antibodies; ENA, extractable nuclear antigens; dsDNA, double-stranded DNA.

Anticardiolipin antibodies are expressed as G antiphospholipid (GPL) and M antiphospholipid (MPL) units (normal values < 10 GPL or MPL units).20

†

Anti-β₂-GPI antibodies are expressed as OD values (normal values < 0.150 for IgG and 0.280 for IgM).20Sera were considered positive if OD values were higher than the 95th percentile of 100 healthy controls.

‡

Antinuclear antibodies were detected by indirect immunofluorescence on Hep2 cells, antiextractable nuclear antigens by counterimmunoelectrophoresis and immunoblot, and anti-dsDNA by indirect immunofluorescence on Crithidia luciliae as described.37-39

View Large

This Feature Is Available To Subscribers Only